{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:46:01Z","timestamp":1778499961125,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00381-023-06061-5","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T05:01:54Z","timestamp":1688446914000},"page":"511-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey"],"prefix":"10.1007","volume":"40","author":[{"given":"Parisa","family":"Sharafi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Varan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Ersoy-Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukriye","family":"Ayter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"6061_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/jmg.33.1.2","volume":"33","author":"MH Shen","year":"1996","unstructured":"Shen MH, Harper PS, Upadhyaya M (1996) Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet 33:2\u201317","journal-title":"J Med Genet"},{"key":"6061_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0888-7543(95)80104-T","volume":"25","author":"Y Li","year":"1995","unstructured":"Li Y, O\u2019Connell P, Breidenbach HH, Cawthon R, Stevens J, Xu G, Neil S, Robertson M, White R, Viskochil D (1995) Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 25:9\u201318","journal-title":"Genomics"},{"key":"6061_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","volume":"15","author":"LM Messiaen","year":"2000","unstructured":"Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, Paepe AD (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15:541\u2013555","journal-title":"Hum Mutat"},{"key":"6061_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/jmedgenet-2012-100978","volume":"49","author":"E Pasmant","year":"2012","unstructured":"Pasmant E, Vidaud M, Vidaud D, Wolkenstein P (2012) Neurofibromatosis type 1: from genotype to phenotype. J Med Genet 49:483\u2013489","journal-title":"J Med Genet"},{"key":"6061_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.2006.00639.x","volume":"70","author":"AB Trovo-Marqui","year":"2006","unstructured":"Trovo-Marqui AB, Tajara EH (2006) Neurofibromin: a general outlook. Clin Genet 70:1\u201313","journal-title":"Clin Genet"},{"key":"6061_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/(SICI)1096-8628(19971128)73:1<80::AID-AJMG16>3.0.CO;2-N","volume":"73","author":"JH Tonsgard","year":"1997","unstructured":"Tonsgard JH, Yelavarthi KK, Cushner S, Short MP, Lindgren V (1997) Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet 73:80\u201386","journal-title":"Am J Med Genet"},{"key":"6061_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1086\/510781","volume":"80","author":"M Upadhyaya","year":"2007","unstructured":"Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, Evans DG, Howard E, Kerr B, Griffiths S, Consoli C, Side L, Adams D, Pierpont M, Hachen R, Barnicoat A, Li H, Wallace P, Van Biervliet JP, Stevenson D, Viskochil D, Baralle D, Haan E, Riccardi V, Turnpenny P, Lazaro C, Messiaen L (2007) An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 80:140\u2013151","journal-title":"Am J Hum Genet"},{"key":"6061_CR8","first-page":"8573","volume":"63","author":"ML Bajenaru","year":"2003","unstructured":"Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, Gutmann DH (2003) Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63:8573\u20138577","journal-title":"Cancer Res"},{"key":"6061_CR9","doi-asserted-by":"publisher","first-page":"8588","DOI":"10.1158\/0008-5472.CAN-06-2220","volume":"67","author":"NM Warrington","year":"2007","unstructured":"Warrington NM, Woerner BM, Daginakatte GC, Dasgupta B, Perry A, Gutmann DH, Rubin JB (2007) Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res 67:8588\u20138595","journal-title":"Cancer Res"},{"key":"6061_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fphar.2015.00153","volume":"6","author":"NM Warrington","year":"2015","unstructured":"Warrington NM, Sun T, Rubin JB (2015) Targeting brain tumor cAMP: the case for sex-specific therapeutics. Front Pharmacol 6:153","journal-title":"Front Pharmacol"},{"key":"6061_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/gim.2012.124","volume":"15","author":"VM Riccardi","year":"2013","unstructured":"Riccardi VM, Lupski JR (2013) Duplications, deletions, and single-nucleotide variations: the complexity of genetic arithmetic. Genet Med 15:172\u2013173","journal-title":"Genet Med"},{"key":"6061_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.mgene.2017.12.003","volume":"15","author":"YK Terzi","year":"2018","unstructured":"Terzi YK, Oguzkan-Balci S, Anlar B, Varan A, Ersoy-Evanse S, Sharafif P, Ayter S (2018) Clinical findings and mutation analysis of NF1 patients in Turkey. Meta Gene 15:80\u201383","journal-title":"Meta Gene"},{"key":"6061_CR13","first-page":"1626","volume":"49","author":"O Sarac","year":"2019","unstructured":"Sarac O, Algin O, Beyazal M, Anlar FB, Varan A, Kansu AT (2019) Assessment of the visual pathways in patients with neurofibromatosis-1 by 3S-space technique with 3-Tesla MRI. Turk J Med Sci 49:1626\u20131633","journal-title":"Turk J Med Sci"},{"key":"6061_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/COC.0b013e3182467efa","volume":"36","author":"A Varan","year":"2013","unstructured":"Varan A, Batu A, Cila A, Soylemezoglu F, Balci S, Akalan N, Zorlu F, Akyuz C, Kutluk T, Buyukpamukcu M (2013) Optic glioma in children: a retrospective analysis of 101 cases. Am J Clin Oncol 36:287\u2013292","journal-title":"Am J Clin Oncol"},{"key":"6061_CR15","doi-asserted-by":"crossref","unstructured":"Upadhyaya M, Osborn M, Maynard J, Harper P (1996) Characterization of six mutations in exon 37 of neurofibromatosis type 1 gene. Am J Med Genet 67:421\u2013423","DOI":"10.1002\/(SICI)1096-8628(19960726)67:4<421::AID-AJMG20>3.0.CO;2-K"},{"key":"6061_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/pbc.21234","volume":"50","author":"R Kebudi","year":"2008","unstructured":"Kebudi R, Tuncer S, Upadhyaya M, Peksayar G, Spurlock G, Yazici H (2008) A novel mutation in the NF1 gene in two siblings with neurofibromatosis type 1 and bilateral optic pathway glioma. Pediatr Blood Cancer 50:713\u2013715","journal-title":"Pediatr Blood Cancer"},{"key":"6061_CR17","doi-asserted-by":"publisher","unstructured":"Han SS, Cooper DN, Upadhyaya MN (2001) Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 ( NF1 ) gene. Hum Genet 109(5):487\u2013497. https:\/\/doi.org\/10.1007\/s004390100594","DOI":"10.1007\/s004390100594"},{"key":"6061_CR18","doi-asserted-by":"publisher","unstructured":"Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, Estivill X, Lazaro C (2003) Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet 40(6):82e\u201382. https:\/\/doi.org\/10.1136\/jmg.40.6.e82","DOI":"10.1136\/jmg.40.6.e82"},{"key":"6061_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000192","volume":"3","author":"C Anastasaki","year":"2017","unstructured":"Anastasaki C, Morris SM, Gao F, Gutmann DH (2017) Children with 5\u2019-end NF1 gene mutations are more likely to have glioma. Neurol Genet 3:e192","journal-title":"Neurol Genet"},{"key":"6061_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/jmg.2010.081760","volume":"48","author":"S Sharif","year":"2011","unstructured":"Sharif S, Upadhyaya M, Ferner R, Majounie E, Shenton A, Baser M, Thakker N, Evans DG (2011) A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet 48:256\u2013260","journal-title":"J Med Genet"},{"key":"6061_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4149\/neo_2013_084","volume":"60","author":"A Bolcekova","year":"2013","unstructured":"Bolcekova A, Nemethova M, Zatkova A, Hlinkova K, Pozgayova S, Hlavata A, Kadasi L, Durovcikova D, Gerinec A, Husakova K, Pavlovicova Z, Holobrada M, Kovacs L, Ilencikova D (2013) Clustering of mutations in the 5\u2019 tertile of the NF1 gene in Slovakia patients with optic pathway glioma. Neoplasma 60:655\u2013665","journal-title":"Neoplasma"},{"key":"6061_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00439-016-1646-x","volume":"135","author":"S Hutter","year":"2016","unstructured":"Hutter S, Piro RM, Waszak SM, Kehrer-Sawatzki H, Friedrich RE, Lassaletta A, Witt O, Korbel JO, Lichter P, Schuhmann MU, Pfister SM, Tabori U, Mautner VF, Jones DTW (2016) No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. Hum Genet 135:469\u2013475","journal-title":"Hum Genet"},{"key":"6061_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/01677063.2018.1456538","volume":"32","author":"P Sharafi","year":"2018","unstructured":"Sharafi P, Ayter S (2018) Possible modifier genes in the variation of neurofibromatosis type 1 clinical phenotypes. J Neurogenet 32:65\u201377","journal-title":"J Neurogenet"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-023-06061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-023-06061-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-023-06061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T11:04:32Z","timestamp":1706871872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-023-06061-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6061"],"URL":"https:\/\/doi.org\/10.1007\/s00381-023-06061-5","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"21 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Ethics Committee of Hacettepe University, ANKARA (report number: GO16\/674\u201307, date: 08.11.2016). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors give the publisher the permission to publish the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Parisa Sharafi, Sibel Ersoy-Evans, Ali Varan, and Sukriye Ayter declare that they have no conflict of financial or non-financial interests that are directly or indirectly related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}